Dr. Elizabeth Brém, an Assistant Professor in the Division of Hematology/Oncology at the University of California Irvine School of Medicine and Dr. Ehab Atallah, a Professor of Medicine and Section Head of Hematological Malignancies in the Medical College of Wisconsin’s Division of Hematology and Oncology join Dr. Charles Turck to explore collaborative approaches and share best practices in the management of chronic lymphocytic leukemia.

The 2021 ESMO Congress featured a lot of new advancements in non-small cell lung cancer (NSCLC) treatment. Here to provide a recap of one of those treatments for NSCLC patients with HER2 mutations is Dr. Alexander Spira, Co-Director of the VCS Research Institute, Director of the Thoracic and Phase I Program, and Clinical Assistant Professor at Johns Hopkins.

Immune checkpoint inhibitor/tyrosine kinase inhibitor combination therapy has forged to the front-line for the management of metastatic RCC and recurrent RCC, but how do clinicians select the ideal treatment regimen for their patients? How does patient risk status influence the decision-making process? This virtual tumor board features a multidisciplinary expert panel presenting a favorable-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize outcomes in this patient population. Faculty additionally cover the importance of incorporating the patient perspective into treatment decisions.

After viewing the activity, visit the Related tab for supplemental resources.

Immunotherapy using checkpoint inhibitors has become a standard of practice in advanced non-small cell lung cancer. But can combination therapy further improve patient outcomes? Dr. Jacob Sands is joined by Dr. Shirish Gadgeel, Chief of the Division of Hematology and Oncology at Henry Ford Cancer Institute, who recently spoke about this topic at the American Society of Clinical Oncology’s annual meeting.

Artificial intelligence-based models have become a growing area of interest in clinical oncology. What do we need to know about them? Dr. Benjamin Kann, a physician at Dana Farber Cancer Institute, and Assistant Professor of radiation oncology at Harvard Medical School, meets with Dr. Jacob Sands to discuss the use of AI in oncology.

Dr. Brian T. Hill, a physician in the Department of Hematology and Medical Oncology at Cleveland Clinic, explores some of the most recent—and ongoing—impacts of the COVID-19 pandemic on treatment decision-making for patients with chronic lymphocytic leukemia.

Dr. Jacob Sands is joined by Dr. Elizabeth Brém, an Assistant Professor in the Division of Hematology/Oncology at the University of California Irvine School of Medicine to explore opportunities and challenges with fixed duration therapy for patients with chronic lymphocytic leukemia.

Dr. Jennifer Caudle is joined by Dr. Lindsey Roeker, a hematologist and medical oncologist at Memorial Sloan Kettering Cancer Center, to discuss evolving outcome measures and critical diagnostic biomarkers in patients with chronic lymphocytic leukemia.

Is frontline treatment for chronic lymphocytic leukemia evolving? Dr. Jacob Sands is joined by Dr. Bruce Cheson, a Scientific Advisor at the Lymphoma Research Foundation, to review the CLL treatment landscape and take a look at emerging data on long-term outcomes.

Dr. Jennifer Caudle is joined by Dr. Jennifer A. Woyach, a professor in the Division of Hematology at Ohio State University, to discuss tailoring treatment to unique populations for patients with chronic lymphocytic leukemia.